The objective of the study was to examine medically managed secondary prevention at one year after coronary artery bypass grafting (CABG). In all, 214 consecutive patients undergoing isolated elective CABG seen four weeks preoperatively and one year postoperatively. Preoperative systolic blood pressure averaged 135 7 20 mmHg, which increased to 148 7 25 mmHg (Po0.0001) as did diastolic pressure (81 7 12 to 87 7 13 mmHg; Po0.0001). Anginal symptoms were reported by 45.1% (Po0.0001) although median severity scored lower In all, 88% with postoperative angina reported dyspnoea against 44% of those without (Po0.0001). Calcium antagonist use was more common in patients with angina (27.2% vs 5.1%; Po0.0001), but not nitrates (P ¼ 0.8695), diuretics (P ¼ 0.4218), digoxin (P ¼ 0.2565), b-blockers (P ¼ 0.0820), or ACE inhibitors (P ¼ 0.7256). Preoperatively 166 patients (80.2%) took aspirin vs 69.2% afterwards (P ¼ 0.0131). Twelve patients (6.5%) received warfarin after operation vs none preoperatively. Two took digoxin (0.97%) preoperatively and 14 (7.7%) postoperatively (P ¼ 0.001) for chronic atrial fibrillation. One of these took warfarin. Longacting nitrate use fell from 63.4% to 15.8% (P o0.0001). Short-acting nitrate use fell similarly (Po0.0001). Preoperatively 37 patients (17.9%) took ACE inhibitors vs 44 postoperatively (24.2%); 39 had not received them before. Preoperatively 48 (23.2%) took diuretics vs 30 (16.5%) postoperatively (P ¼ 0.127); 24 had not previously taken diuretics. More patients took HMGCoA inhibitors postoperatively (P ¼ 0.0068) and total cholesterol was significantly reduced with a concomitant increase in HDL fraction. Smoking habit was virtually unchanged from 17.8% to 15.1% (P ¼ 0.5023). In conclusion: angina was common. Apart from statin prescribing, postoperative secondary prevention measures were poorly applied, less widespread and less effective than preoperatively. The implications are disturbing.
Introduction
In this prospective observational study, we examined the prescription of anti-anginal drugs preoperatively compared to at one year after operation and the extent to which medically managed secondary prevention measures, including control of hypertension and hyperlipidaemia, were achieved in this patient group.
We have previously shown a relatively high incidence of self-reported cardiovascular symptoms including angina (45.1%) and dyspnoea (63.7%), following coronary artery bypass grafting (CABG); there was also a disturbingly high rate of persistent cigarette smoking at 23%. 1 CABG has been an accepted treatment for angina pectoris for more than 25 years, with improved immediate results in terms of mortality and morbidity 2 as well as improved long-term survival. Following CABG, in most circumstances, it is usual practice to discontinue anti-anginal therapy as it is anticipated that symptoms will be relieved as a result of the procedure. However, several classes of anti-anginal therapy have an antihypertensive effect and indeed may have been prescribed for their antihypertensive properties. Therefore, the removal of this therapy may reveal elevated levels of blood pressure that exceed target levels. 3, 4 This may be particularly problematic if there is no follow-up monitoring of blood pressure or previously documented history of hypertension. Hypertension is a major modifiable risk factor for the development and progression of the underlying disease process, atherosclerosis, and has been shown to increase mortality at two years post-CABG 5 and significantly lower quality of life. 6 We therefore examined the medically administered secondary prevention measures adopted by the local health-care workers and the management of these symptoms as they occurred. We compared pre-and postoperative drug prescribing and looked for evidence of a structured or rational strategy.
Methods

Sample and size
A consecutive sample of patients (n ¼ 214) was recruited over a six month period from the surgical waiting list for CABG at one cardiac surgical centre according to the following inclusion criteria:
1. Isolated CABG procedure. 2. Elective operation. 3. Residence within approximately 50 miles of the hospital. 4. Expected date for operation was estimated to be approximately four weeks after preoperative assessment for the study.
All patients invited to participate in the study agreed to take part and written informed consent was provided. Demographic details (age, sex, postcode) were collected from the patients' medical records. Patients were interviewed prior to operation (4 weeks) and postoperative (1 year).
The median number of grafts [interquartile range] was 3 [3] [4] per patient.
CHD risk factors
Self-reported tobacco smoking habit was recorded. Blood pressure was measured in accordance with the British Hypertension Society guideline 3 by the same person (GL) on both occasions. Plasma cholesterol level was measured from a venous blood sample at the Institute of Biochemistry, Glasgow Royal Infirmary NHS Trust, using standardised protocols and internationally agreed quality assurance procedures. The patients were weighed in light clothes without shoes to the nearest 0.1 kg and height was measured in cm to the nearest 0.5 cm. Body mass index (kg/m 2 ) was derived from these measurements.
Drugs
Patients were asked to complete a form indicating the medications that they were currently prescribed.
Self-reported levels of symptoms
A visual analogue scale 7 consisting of a horizontal continuous line ranging from 0 to 7, where 0 represents 'no effect on overall well-being and health' and 7 represents 'complete disability, discomfort and restriction to life', was constructed for the self-reporting of angina and breathlessness symptoms. Respondents were asked to indicate the severity of their symptoms at the time of interview by placing a mark on the scale. This is different from the CCC 8 and NYHA 9 classifications but it provides a means of documenting patients' perceived symptom severity. 
Statistical analysis
Results
Patient descriptors
The average age was 58.2 7 7.7 years; 79% were men. A prior diagnosis of definite MI was known in 63.2% of the study group, while 33% had no history and 3.8% uncertain diagnosis. NYHA grading was grade 1 in 0%, grade 2 in 40.7%, grade 3 in 42.6%, grade 4 in 1.9%. Of the patients, 12.6% were diabetic (an incidence of 11.2% in males and 18.2% in females), 40.1% had systolic blood pressure greater than or equal to 140 mmHg with 11.9% exceeding 160 mmHg, 30.0% had diastolic blood pressure greater than or equal to 90 mmHg with 9.0% having diastolic pressure greater than or equal to 100 mmHg at preoperative assessment.
As previously reported smoking habit was virtually unchanged. 1 
Blood pressure control
Before operation the mean systolic blood pressure averaged 135 7 20 mmHg. At follow-up, this had risen to 148 7 25 mmHg (Po0.0001). Mean diastolic pressure before operation was 81 7 12 mmHg but by one year had risen similarly to 87 7 13 mmHg (Po0.0001); see Figure 1 .
Postoperative blood pressure was analysed in terms of antihypertensive therapy as follows: the data set was split between those prescribed the specified drug type at follow-up vs those not taking that class of agent. For b-blockers, average systolic blood pressure on follow-up, in those treated, was 147 7 25 mmHg against 150 7 23 mmHg in untreated patients (P ¼ 0.6410). For patients taking calcium channel blockers, mean systolic blood pressure was 145 7 21 mmHg vs 148 7 25 mmHg for those patients not taking the drug (P ¼ 0.6300). For patients receiving ACE-inhibitors blood pressure averaged 145 7 22 mmHg as opposed to 148 7 25 mmHg in untreated patients (P ¼ 0.4725).
Vasoactive and anti-anginal drugs
Postoperatively, 97 patients (53%) took no form of antihypertensive or anti-anginal agent. Seventy took a single agent, 15 took two drugs and one patient took triple therapy. Mean blood pressure in untreated patients was 145 7 22 mmHg, in patients receiving monotherapy it was 149 7 27 mmHg, and in those taking two drugs it was 153 7 21 mmHg (P ¼ 0.4899 by anovar). Those whose systolic blood pressure was 141 mmHg or higher represent 54% of the sample, whereas for diastolic blood pressure 91 mmHg and over this proportion was 34%. If we look at 140 or 90 mmHg and over, these proportions change to 60% and 43%, respectively. These figures represent significant increases upon the proportion of patients known to require antihypertensive treatment preoperatively both for systolic pressure (P ¼ 0.01; Fisher exact) and for diastolic pressure (P ¼ 0.01; Fisher exact).
The individual drug treatments are presented below and in Table 1 .
L-type calcium channel blockers. The use of these agents fell from 77.8% before operation to 14.3% (Po0.0001; Fisher exact test) afterwards, in keeping with blanket removal of anti-anginal agents postoperatively.
b-blockers. These drugs were taken by only 58.5% of patients preoperatively and by 17.0% at one year afterwards (Po0.0001). It is of interest that patients on b-blockers preoperatively spent less time on the waiting list (192 7 109 vs 232 7 115 days; P ¼ 0.012) than those not receiving these agents. The association of b-blockade with shorter pre-operative waiting times suggests that these patients were more likely to have symptoms of unstable angina and were thus regarded as more urgent.
Nitrates. The use of long-acting nitrates preoperatively was 63.4% and postoperatively was 15.8% (Po0.0001). Short-acting nitrate use fell similarly from 88.5% to 16.4% (Po0.0001). Thus, the medically identified and treated recurrent angina rate at one year was around 16%, as these drugs are used specifically to relieve symptoms of myocardial ischaemia.
ACE inhibitors. Before operation 37 patients (17.9%) were taking an ACE inhibitor and 44 patients (24.2%) received a drug of this class afterwards. However, only five of those taking these drugs preoperatively were represcribed them postoperatively; thus new prescriptions account for the remainder (see Figure 2) . K ATP channel inhibitors. These agents were only used in 3.3% of preoperative and 2.7% of postoperative patients and have been excluded from general analysis.
Diuretic use
In total, 48 patients (23.2%) were taking diuretics preoperatively compared to 30 (16.5%) postoperatively (P ¼ 0.127), of whom 24 had not previously taken diuretics (see Table 1 ). Because of the known association between ankle swelling and L-type calcium antagonists, we looked at those patients in whom calcium antagonists were the only anti-anginal drug vs patients exclusively taking Negating the benefits of CABG? PR Belcher et al b-blockers but no significant associations with diuretic use could be detected. The reason we were unable to associate diuretic use as a result of ingestion of calcium antagonists is possibly because the diuretic had been prescribed for hypertension in the first place.
Use of antiplatelet agents or anticoagulants
Preoperatively, 166 patients (80.2%) took aspirin; one took persantin and in five it was unknown whether antiplatelet treatment was being given. Forty patients (18.9%) took no antiplatelet drug. Postoperatively 69.2% took aspirin while 30.8% were receiving no antiplatelet drug (P ¼ 0.0131; Fisher exact test). No patient took warfarin before operation but 12 (6.5%) were recorded as taking the drug one year after operation; eight of these also took aspirin (see Table 1 ).
Treatment of arrhythmias
Digoxin was taken by two patients (0.97%) preoperatively and 14 (7.7%) postoperatively (P ¼ 0.001; Fisher exact test) for chronic atrial fibrillation. This is approximately equal to the number taking warfarin postoperatively 10 but only one patient took both drugs (see Table 1 ).
Cardiac symptoms
Anginal pain (see Table 2 ) was reported to us by 45% of patients at one year follow-up compared to 100% preoperatively (Po0.0001), although the median self-rated score was reduced from that recorded preoperatively Table 2 . Only eight patients (4.5%) reported breathlessness as a new symptom and 34.3% with persistent dyspnoea were improved. The presence of postoperative breathlessness was reported by 88% of patients with postoperative angina but in only 44% of those without chest pain (Po0.0001). Systolic and diastolic blood pressure were virtually identical in both these groups of patients (P ¼ 0.5915 and 1, respectively).
Drug therapy at follow-up was examined according to the presence or absence of anginal symptoms and dyspnoea. Calcium channel blockers were prescribed more frequently in patients with angina (27.2% vs 5.1%; P o0.0001). Significant differences in prescribing could not be detected with respect to angina for antiplatelet agents (P ¼ 0.8695), diuretics (P ¼ 0.4218), digoxin use (P ¼ 0.2565), b-blockers (P ¼ 0.0820), or ACE inhibitors (P ¼ 0.7256). Of patients reporting postoperative angina, 63% were receiving no form of anti-anginal therapy.
The association of postoperative breathlessness with different drug therapies was examined. Calcium channel blockers were more frequently prescribed (19.3% vs 7.7%; P ¼ 0.0494) in those patients who reported dyspnoea. However, no such association could be made for antiplatelet drugs (P ¼ 0.3094), diuretic use (P ¼ 0.2990), digoxin (P ¼ 1), b-blockade (P ¼ 0.6854), or ACE inhibitors (P ¼ 0.5905).
Lipid lowering agents and cholesterol targets
Patients taking these drugs (all classes) numbered 34 preoperatively (16.3%). Two took a fibrate whereas the rest were prescribed a statin. The proportion of patients taking a HMG-CoA inhibitor rose to 27.9% Pre: preoperative; Post: postoperative. Angina severity score from 0 to [7] 7. Dyspnoea severity with angina (+angina) vs without angina (Àangina). Negating the benefits of CABG? PR Belcher et al at one year postoperative (P ¼ 0.0068), thus indicating a new intervention in these patients. Preoperatively 73.4% of patients had total cholesterol concentrations exceeding target levels of 5.0 mM/l. Postoperatively, this had improved significantly and was accompanied by a significant rise in HDL fraction.
Discussion
The main finding of this study was the poor application of medically managed secondary prevention measures postoperatively. It was also noted that patients' perceptions of recurrence of angina and associated dyspnoea 1 were more common than usually reported. 11, 12 Preoperatively, patients may have had angina for several years. Many of the drugs used to treat angina are also those used for the treatment of hypertension. Normal preoperative blood pressure either indicates normotension or successful treatment of hypertension. Therefore, the true incidence of preoperative hypertension is probably unknown although two-fifths of the patients were diagnosed as hypertensive preoperatively. This proportion was significantly higher at follow-up. Therefore, unrecognised hypertension may develop and be revealed by the practice of blanket withdrawal of anti-anginal therapy postoperatively. It is thus not surprising that blood pressure rises were recorded but disappointing that they had escaped the notice of primary care physicians, cardiac surgeons, cardiologists and rehabilitation schemes. Hypertension is a major modifiable risk factor for the development and progression of the underlying disease process, atherosclerosis, 10, 13 and has been shown to increase mortality at two years post-CABG 5 and significantly lower the quality of life. 6 The adequate treatment of hypertension is associated with increased wellbeing 14 and reduction in stroke, 15 myocardial infarction, 16 and left ventricular hypertrophy. 17 It was surprising that significantly fewer patients were receiving antiplatelet therapy after operation than before. This was far below the EURASPIRE targets 18, 19 and also represents a failure of supervision. The use of anticoagulants is more complex: potential indications for these drugs include endarterectomy, detection of intraventricular thrombus, deep vein thrombosis and atrial fibrillation. It is thus a matter of concern that of the 12 patients being treated with digoxin for chronic atrial fibrillation, only one was receiving warfarin. This again falls well short of published guidelines. 20, 21 Improvement in the management of lipids was noted. While moderately encouraging, this still represents a shortfall in prescribing because 61.2% of patients postoperatively had total cholesterol concentrations exceeding target levels of 5.0 mM/l. The effect of statin drugs on improving survival in subjects with coronary artery disease is clear. 22 Although target values are not being met universally, others are doing better than we are. 23 It is becoming evident that statins also have protective effects that are unrelated to levels of cholesterol. [23] [24] [25] The recurrent angina rate, as determined by nitrate use, is lower than the self-reported presence of symptoms postoperatively but, as stated in the Methods section, symptom severity levels were assessed on a subjective seven-point scale which is not the same as the Canadian Cardiovascular Criteria 8 scale. We are unclear as to the level of severity that would cause the patient to seek medical advice. This may be a problem of low expectations in that complete relief of angina was not expected. The presence of postoperative breathlessness was reported by 88% of patients with postoperative angina but in only 44% of those without chest pain (Po0.0001). It is recognised that these symptoms commonly occur together and that dyspnoea is a consequence of myocardial ischaemia. 26 Diuretic use was not associated with dyspnoea. The indication for diuretic therapy in this group of patients preoperatively was control of hypertension but they are also prescribed in an attempt to control ankle oedema secondary to the use of calcium antagonists, especially amlodipine, although proof of the efficacy of diuretics in this situation is missing. 27 The decreased use of calcium antagonists postoperatively may possibly explain the decreased use of diuretics although we were unable to demonstrate this statistically.
Overall the picture revealed by this study does not compare favourably with other follow-up studies. [28] [29] [30] Improvements in present practice might be achieved by a better monitoring of blood pressure after operation. We recommend that blood pressure be monitored more frequently than once at the six week surgical postoperative visit. Improvements in the present practice could be made by adherence to reportedly successful treatment regimens such as the HOT study 16 and the British Hypertension Society Guidelines: these stipulate that for hypertensives with additional risk factors (such as coronary artery disease), the target blood pressure should be 140/90 mmHg or below. The HOT study has also shown that fewer than 50% of hypertensive patients will be controlled on monotherapy and one-third will require three or more drugs; 16 we found only one patient on triple therapy. The most disappointing aspect of this study was that antihypertensive treatment was inadequate, continuity of prescribing was virtually absent although indications for some drugs, such as diuretics, preoperatively were unclear. One striking feature was that nearly all the patients who were taking ACE inhibitors preoperatively were not represcribed them postoperatively. Most units routinely stop ACE inhibitors before operation because of their profound hypotensive effects during cardiopulmonary bypass. Possibly because hypertension does not manifest itself in the first few days after operation, it is easy to overlook this important part of secondary prevention. However, it is curious that a similar proportion of patients were started de novo on these drugs postoperatively.
Nurse-led programmes of shared care for patients awaiting bypass surgery, 31 and secondary prevention clinics for patients with CHD in the community 32 can effectively improve CHD risk factors including smoking status. Such models of care could be considered for the postoperative management of patients following CABG. Although cardiac rehabilitation programmes have a remit for secondary prevention, attendance rates may be low and outcome data for secondary prevention targets are not routinely available.
We conclude that our present management of secondary prevention in post-coronary artery bypass patients is poor. More considered replacement of anti-anginal drugs with concomitant antihypertensive effects is mandated. There is little excuse for the decreased use of antiplatelet agents and lack of anticoagulation for those in chronic atrial fibrillation. Better follow-up and continuity of care are required, probably by the use of nurse-led programmes. Until risk factors are properly controlled, long-term outcomes will remain jeopardised and cost-benefit analysis of these procedures will be adversely affected.
